高血压伴糖尿病肾病预防与治疗优选.pptVIP

科素亚（氯沙坦钾） ——高血压伴糖尿病肾病的优选 ;氯沙坦——高血压伴糖尿病肾病的优选;流行病学;高血压增加糖尿病肾病患者ESRD或死亡的风险;氯沙坦钾——高血压伴糖尿病肾病的优选;;氯沙坦钾;氯沙坦钾; 平稳降压，具有较高的谷峰比(T/P值);双重阻断，更强、更平稳、更持久降压;氯沙坦钾——高血压伴糖尿病肾病的优选;Schiller et al, 1999 dePablos Velasco et al, 1998 Buter et al, 2000 Esmatjes et al, 2001 Lozano et al, 2001 Ersoy et al, 1999 Kosicka et al,1999 LaCouciere et al, 2000 Grinstein et al, 1999 Hortal et al, 1998 Fauvel et al, 1996 Erley et al, 1995 Bauer et al, 1995 Chan et al, 1995 ;氯沙坦钾  ——有效降低高血压伴2型糖尿病患者蛋白尿;氯沙坦钾 ——显著降低各种肾功能阶段蛋白尿;氯沙坦钾——持续显著降低蛋白尿;;IDNT研究厄贝沙坦平均剂量300mg降低蛋白尿与安慰剂比无显著性差异;氯沙坦钾——高血压伴糖尿病肾病的优选;为什么关注ESRD单项肾脏终点指标？;月;COZAAR (losartan) Nephropathy in Type 2 Diabetic Patients: RENAAL “The primary endpoint of the study was the time to first occurrence of any one of the following events: doubling of serum creatinine, end-stage renal disease (ESRD) (need for dialysis or transplantation), or death. Treatment with COZAAR resulted in a 16% risk reduction in this endpoint (see Figure 4 and Table 3). Treatment with COZAAR also reduced the occurrence of sustained doubling of serum creatinine by 25% and ESRD by 29% as separate endpoints, but had no effect on overall mortality.” From US FDA Product Insert ;总 结;谢 谢